Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Zyprexa injection cost?

See the DrugPatentWatch profile for Zyprexa

What does Zyprexa (olanzapine) injection usually cost?

Zyprexa’s price depends heavily on (1) whether you mean the prescription drug product brand Zyprexa vs. the generic olanzapine, (2) the country and pharmacy, (3) the dose size (mg) and number of vials, and (4) whether you’re paying cash or using insurance. Because pricing varies by location and coverage, the most useful next step is getting the exact product and strength you need from the prescription (for example, the vial strength and quantity), then checking local cash/self-pay pricing or your insurer’s formulary copay.

How much is it with insurance vs. paying cash?

With insurance, patients usually pay a copay or coinsurance based on the plan’s formulary tier. Without insurance, you typically pay the full pharmacy price, which can be much higher. If you tell me your country (and, if in the US, your ZIP code) and the exact vial strength on the prescription, I can help you identify what to look for on pharmacy price lists and how to estimate out-of-pocket cost.

What to ask the pharmacy to get the real out-of-pocket price quickly

Ask the pharmacist for the total price for “Zyprexa injection” using:
- the exact strength (mg) and vial size
- the quantity (number of vials)
- your insurance information (or “cash price” if paying without insurance)
- whether any patient assistance or discount program applies

This avoids confusion with other formulations (Zyprexa tablets vs. injection).

Is there a generic equivalent and does that lower cost?

In many places, olanzapine injection may be available from other manufacturers or as an alternative formulation, which can reduce cost versus the branded product depending on your local market and insurance coverage. The key is matching the product form (injection) and strength.

If you want, I can estimate more precisely—what I need from you

Reply with:
1) Your country (and ZIP code if in the US)
2) The prescription strength (mg) and how many vials
3) Insurance yes/no (and copay/plan name if you know it)

Then I’ll tell you the most likely price drivers and the fastest way to get an accurate number at your local pharmacy.

Sources

No sources were provided with your question, so I can’t cite pricing figures reliably.



Other Questions About Zyprexa :

Zyprexa cost per month? Zyprexa vs abilify? Zyprexa cost? Generic for zyprexa? Side effects of zyprexa? Zyprexa relprevv cost? Zyprexa generic?

AI-Drug Label Prescribing Information Alignment Report

98
98%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The claim is directly supported by FDA labeling in Warnings and Precautions (5.1), Geriatric Use (8.5), and Patient Counseling (17), including the increased mortality statement and inclusion of ZYPREXA/olanzapine-treated patients.


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent
AdverseReactions
95
Excellent

Accurate Statements

Increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs (including ZYPREXA/olanzapine).
Supported by label language in 5.1 (Elderly Patients with Dementia-Related Psychosis: Increased Mortality), 8.5 (Geriatric Use), and 17 (Patient Counseling Information).
ZYPREXA/olanzapine-treated elderly patients with dementia-related psychosis have increased risk of death compared with placebo, with higher death incidence in placebo-controlled trials (3.5% vs 1.5%).
Supported by 5.1 and reiterated in 8.5.

Unsupported Statements


Contradictions


Important Omissions

The claim does not mention the label’s additional context that ZYPREXA is not approved for dementia-related psychosis treatment (explicitly stated in 5.1, 8.5, and 17).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The statement reflects an FDA-labeled boxed warning/precaution about increased mortality risk in the specified population and does not instruct use in an off-label way.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omission of the label’s explicit statement that ZYPREXA is not approved for elderly patients with dementia-related psychosis.

Suggested Improvement
Add the labeling qualifier that ZYPREXA is not approved for the treatment of dementia-related psychosis (as stated in 5.1, 8.5, and 17).